Inhaled prostacyclin for Eisenmenger syndrome complicated with miliary tuberculosis

Eva M. Marwali; Novik Budiwardhana; Anna U. Rahayoe

doi:10.14238/pi51.4.2011.241-4

Eva M. Marwali Division of Cardiac Critical Care Medicine, Department of Child Health, National Cardiovascular Center, Harapan Kita Hospital, Jakarta
Novik Budiwardhana Division of Cardiac Critical Care Medicine, Department of Child Health, National Cardiovascular Center, Harapan Kita Hospital, Jakarta
Anna U. Rahayoe Division of Pediatric Cardiology, Department of Cardiology, National Cardiovascular Center, Harapan Kita Hospital, Jakarta, Indonesia.2

DOI: https://doi.org/10.14238/pi51.4.2011.241-4

Keywords: inhaled prostacyclin, Eisenmenger syndrome, miliary tuberculosis

Abstract

Eisenmenger syndrome occurs in patients with large congenital cardiac or extracardiac left-to-right shunts. Clinically, Eisenmenger syndrome is characterized by multiple organ involvement and progressive deterioration of function over time. In the advanced stages, signs and symptoms of Eisenmenger syndrome include central cyanosis, dyspnea, fatigue, hemoptysis, syncope and right-sided heart failure. Survival of patients with Eisenmenger syndrome is generally poor, but appears to be better than that of patients with idiopathic pulmonary arterial hypertension (PAH) in a comparable functional class.1

References

1. Galie N, Manes A, Palazzini M, Negro L, Marinelli A, Gambetti S, et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmengerâ€™s syndrome. Drugs. 2008;68;1049-66.
2. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:332-9.
3. Olschweski H, Ghofrani A, Schmehl T, Winkler J, Wilkens H, Hoper MM, et al. Inhaled iloprost to treat severe pulmonary hypertension: an uncontrolled trial. Ann Intern Med. 2000;132:435-43.
4. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetther E, Niedermeyer J, et al. Long-term treatment of pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342:1866-70.
5. B Beghetti M, Berner M, Rimensberger PC. Long term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusion. Heart 2001;86:e10.
6. Beghetti M, Nicod L, Barazzone-Argiroffo C, Rimensberger PC. New combined treatments avoid transplantation in a child with severe pulmonary hypertension. Heart. 2004;90:154.
7. Emmel M, Keuth B, Schickendantz S. Paradoxical increase of pulmonary vascular resistance during testing of inhaled iloprost. Heart. 2003;90:e2.
8. R Rimensberger PC, Spahr-Schophfer I, Berner M, Jaeggi E, Kalangos A, Friedli B, et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation. 2001;103:544-8.
9. Hallioglu O, Dilber E, Celiker A. Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. Am J Cardiol. 2003;92:1007-9.